These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 829620

  • 1. [Depot fluphenazine as a means of stabilizing remission in cases of schizophrenia].
    Vovin RIa, Vovina EN.
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():183-7. PubMed ID: 829620
    [Abstract] [Full Text] [Related]

  • 2. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR, Levine J.
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [Abstract] [Full Text] [Related]

  • 3. [Results of therapy with Lyogen-Depot in schizophrenic diseases].
    Friemert K, Beier R, Vehreschild T.
    Psychiatr Neurol Med Psychol (Leipz); 1974 Jun; 26(6):374-7. PubMed ID: 4849639
    [No Abstract] [Full Text] [Related]

  • 4. [Experience with the depot neuroleptic LyogenR-depot].
    Bach O, Petermann H, Geppert V.
    Psychiatr Neurol Med Psychol (Leipz); 1978 Sep; 30(9):563-6. PubMed ID: 733993
    [Abstract] [Full Text] [Related]

  • 5. Dosage and side effect comparisons betweel oral and depot fluphenazine.
    Schooler NR, Levine J.
    Psychopharmacol Bull; 1977 Jul; 13(3):29-31. PubMed ID: 329328
    [No Abstract] [Full Text] [Related]

  • 6. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 7. [Effect of moditen-depot therapy on the duration and quality of remissions in schizophrenia patients].
    Vovin RIa, Gurovich IIa, Eryshev OF, Zaĭtsev SG, Magalif AIu.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1977 Jul; 77(5):743-9. PubMed ID: 899478
    [Abstract] [Full Text] [Related]

  • 8. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B.
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [Abstract] [Full Text] [Related]

  • 9. Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].
    Schooler NR, Levine J, Severe JB.
    Psychopharmacol Bull; 1979 Apr; 15(2):44-7. PubMed ID: 373006
    [No Abstract] [Full Text] [Related]

  • 10. Our experience with Moditene-Depot in chronic schizophrenia.
    Gamkrelidze ShA, Putkoradze-Gamkrelidze NA.
    Act Nerv Super (Praha); 1973 Aug; 15(3):169. PubMed ID: 4769133
    [No Abstract] [Full Text] [Related]

  • 11. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa, Minsker EI, Panteleeva GP, Mazurskii MB, Pekunova LG.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973 Aug; 73(5):753-8. PubMed ID: 4718619
    [No Abstract] [Full Text] [Related]

  • 12. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH, Gelder MG.
    Adv Biochem Psychopharmacol; 1980 Aug; 24():599-602. PubMed ID: 7405678
    [No Abstract] [Full Text] [Related]

  • 13. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK, Wong KE, Tay WK, Gill RC.
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [Abstract] [Full Text] [Related]

  • 14. [Characteristics of the psychotropic activity of long-acting drugs (experience in the use of Moditen-depot)].
    Smulevich AB, Minsker EI, Mazaeva NA, Volkova RP, Lukanina SK.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972 Oct; 72(6):912-20. PubMed ID: 5050051
    [No Abstract] [Full Text] [Related]

  • 15. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R.
    Adv Biochem Psychopharmacol; 1980 Oct; 24():483-93. PubMed ID: 6996445
    [No Abstract] [Full Text] [Related]

  • 16. Early hospital experience with fluphenazine decanoate.
    Small JG, Kellams J.
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [Abstract] [Full Text] [Related]

  • 17. [Results of the use of fluphenazine in a depot preparation].
    Marcjan K, Pietruszewska I, Wolak E.
    Psychiatr Neurol Med Psychol Beih; 1975 Oct; 20-21():176-82. PubMed ID: 829619
    [Abstract] [Full Text] [Related]

  • 18. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective.
    Dencker SJ.
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):22-7. PubMed ID: 6143744
    [Abstract] [Full Text] [Related]

  • 19. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
    Marder SR, Van Putten T, Aravagiri M, Hubbard JW, Hawes EM, McKay G, Midha KK.
    Psychopharmacol Bull; 1989 May; 25(3):479-82. PubMed ID: 2626520
    [Abstract] [Full Text] [Related]

  • 20. Maintenance treatment of schizophrenia with long-acting fluphenazine.
    Niturad A, Ciurezu T, Cucu I.
    Act Nerv Super (Praha); 1974 Aug; 16(3):167. PubMed ID: 4154028
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.